WO2011153345A3 - A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients - Google Patents
A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients Download PDFInfo
- Publication number
- WO2011153345A3 WO2011153345A3 PCT/US2011/038922 US2011038922W WO2011153345A3 WO 2011153345 A3 WO2011153345 A3 WO 2011153345A3 US 2011038922 W US2011038922 W US 2011038922W WO 2011153345 A3 WO2011153345 A3 WO 2011153345A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene expression
- expression profile
- brca
- ness
- responsiveness
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Aspects of the invention provide methods and compositions for evaluating cells and tissues based on gene expression profiles to determine their sensitivity or resistance to one or more chemotherapeutic agents. A patient having a tumor or cancer can be evaluated using a gene expression profile to assist in determining the disease prognosis, selecting an appropriate therapy, and/or predicting drug resistance or sensitivity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35128210P | 2010-06-03 | 2010-06-03 | |
US61/351,282 | 2010-06-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011153345A2 WO2011153345A2 (en) | 2011-12-08 |
WO2011153345A3 true WO2011153345A3 (en) | 2012-03-15 |
Family
ID=45067295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/038922 WO2011153345A2 (en) | 2010-06-03 | 2011-06-02 | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011153345A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170058351A1 (en) * | 2013-11-28 | 2017-03-02 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Methods for Molecular Classification of BRCA-Like Breast and/or Ovarian Cancer |
AU2015369624A1 (en) * | 2014-12-23 | 2017-06-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
GB2553736A (en) | 2015-05-19 | 2018-03-14 | S Sridhar T | Method for identification of a deficient BRCA1 function |
WO2019079297A1 (en) | 2017-10-16 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
US20230346980A1 (en) * | 2022-04-29 | 2023-11-02 | Tiba Biotech | Tail-conjugated rnas |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060246470A1 (en) * | 2004-12-06 | 2006-11-02 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
-
2011
- 2011-06-02 WO PCT/US2011/038922 patent/WO2011153345A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060246470A1 (en) * | 2004-12-06 | 2006-11-02 | Suzanne Fuqua | RNA expression profile predicting response to tamoxifen in breast cancer patients |
Non-Patent Citations (1)
Title |
---|
MARKMAN ET AL.: "Second-Line Treatment of Ovarian Cancer", THE ONCOLOGIST, vol. 5, no. 1, 2000, pages 26 - 35 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011153345A2 (en) | 2011-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013166186A8 (en) | Method for determining complete response to anticancer therapy | |
WO2011153545A3 (en) | Gene expression signature as a predictor of chemotherapeutic response in breast cancer | |
WO2011088149A3 (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
MY180365A (en) | Markers of tumor cell response to anti-cancer therapy | |
EP2908132A3 (en) | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures | |
MX2009002936A (en) | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors. | |
WO2008106175A3 (en) | Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors | |
MX343801B (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer. | |
EP3208615A3 (en) | Uses of labeled hsp90 inhibitors | |
NZ617003A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
WO2011153345A3 (en) | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients | |
BR112012020373A2 (en) | isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tata419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent | |
EP2198021A4 (en) | Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis | |
MX356866B (en) | P53 biomarkers. | |
MX339427B (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer. | |
WO2008073177A3 (en) | Expression profiles associated with irinotecan treatment | |
WO2012074904A3 (en) | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents | |
BR112014027905A2 (en) | antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent. | |
WO2013071012A3 (en) | Personalized strategic cancer treatment | |
MX2012007940A (en) | Tumor tissue based biomarkers for bevacizumab combination therapies. | |
EP3004394A4 (en) | Assays, methods and kits for analyzing sensitivity and resistance to anti-cancer drugs, predicting a cancer patient's prognosis, and personalized treatment strategies | |
WO2008095049A3 (en) | Reagents and methods for predicting drug resistance | |
SG11201400919RA (en) | Patient stratification and determining clinical outcome for cancer patients | |
NZ748624A (en) | Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells | |
WO2016145308A3 (en) | Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11790404 Country of ref document: EP Kind code of ref document: A2 |